Authors: O. Yu. Savelyeva, P. A. Bezditko, Yu. A. Babak, Kharkiv National Medical University
Acute inflammatory diseases of the eyeball and its adnexa are a fairly common childhood pathology. Of these, ophthalmopediatricians most often (almost half of the visits) encounter conjunctivitis and dacryocystitis in newborns [3]. According to the analysis of the incidence and prevalence of diseases of the organ of vision and its adnexa among the child population of Ukraine in 2010–2011, inflammatory diseases of the conjunctiva and dacryocystitis tend to increase [1]. Dacryocystitis is usually diagnosed between the ages of 0 and 6 months, and acute conjunctivitis is diagnosed in children under 6 years of age, with a peak incidence between 12 and 36 months of age [5]. It should be noted that conjunctivitis and dacryocystitis of newborns constitute a special group of inflammatory diseases of the eye and its adnexa, the medical and social significance of which is determined by their high prevalence, recurrent course, the possibility of generalization of the infectious process due to the peculiarities of local and general immunity of the newborn organism, the danger of visual impairment. and in the end, blindness [2]. Unfortunately, recently the number of conjunctivitis in newborns and children of the first year of life, caused by gonococcal, chlamydial and mycoplasmal microflora, has significantly increased [6]. Changing the etiology of acute inflammatory diseases of the conjunctiva and dacryocystitis, often uncontrolled use of broad-spectrum antibiotics for both therapeutic and prophylactic purposes leads to the emergence of resistant strains of microorganisms and, accordingly, to a decrease in the effectiveness of treatment.
Correctly and timely diagnosis, early appointment of effective etiopathogenetically substantiated therapy can avoid complications that are dangerous for the health and life of the child.
However, despite the appearance on the pharmaceutical market of new, fairly effective antibacterial drugs, their use in pediatric ophthalmic practice is often difficult due to age restrictions, the presence of allergic, toxic and other adverse reactions.
Thus, the treatment of acute conjunctivitis and dacryocystitis in young children remains an urgent problem in ophthalmic pediatrics. In this regard, our attention was drawn to the preparations “Floximed” and “Tobrimed” of the World Medicine company.
Keywords: dacryocystitis of newborns, bacterial conjunctivitis in children, floximed, tobrimed